FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128573330> ?p ?o ?g. }

• W2128573330 abstract "Artemether-lumefantrine and artesunate-amodiaquine are first-line treatment for uncomplicated malaria in Cameroon. No study has yet compared the efficacy of these drugs following the WHO recommended 42-day follow-up period. The goal of this study was to compare the clinical efficacy, tolerability and safety of artesunate-amodiaquine (ASAQ), artemether-lumefantrine (AL) and dihydroartemisinin piperaquine (DHAP) among children aged less than ten years in two malaria-endemic ecological regions of Cameroon. A three-arm, randomized, controlled, non-inferiority trial was conducted among children of either gender aged six months (>5 kg) to ten years (n = 720) with acute uncomplicated Plasmodium falciparum infection. Parents/guardians of children provided consent prior to randomization to receive ASAQ, DHAP or AL in the ratio of 2:2:1, respectively. Treatment outcome was assessed based on standard WHO 2003 classification after 42 days of follow-up. The primary outcome was PCR-corrected day-42 cure rates. The non-inferiority, one-sided, lower limit asymptotic 97.5% confidence interval (CI) on the difference in PCR-corrected cure rates of ASAQ and DHAP when compared to AL was accepted if the lower limit of the CI was greater than −10%. Secondary outcomes were parasite and fever clearances and day 7 haemoglobin changes. PCR-corrected PP cure rates of 96.7, 98.1 and 96.3, respectively, for AL, ASAQ and DHAP was observed. The lower bound of the one-sided 97.5% CI calculated around the difference between day-42 cure rate point estimates in AL and ASAQ groups, AL and DHAP groups were, −6% and −4% respectively. There were no statistical significant differences in parasite or fever clearance times between treatments, although fever clearance pattern was different between ASAQ and DHAP. No statistical significant differences were observed in the occurrence of adverse events among treatment groups. ASAQ and DHAP are considered safe and tolerable and are not inferior to AL in the treatment of uncomplicated P. falciparum malaria in Cameroonian children. NCT01845701" @default.
• W2128573330 created "2016-06-24" @default.
• W2128573330 creator A5002294564 @default.
• W2128573330 creator A5007865736 @default.
• W2128573330 creator A5012747021 @default.
• W2128573330 creator A5013524950 @default.
• W2128573330 creator A5033765931 @default.
• W2128573330 creator A5039722694 @default.
• W2128573330 creator A5043434594 @default.
• W2128573330 creator A5047557149 @default.
• W2128573330 creator A5048035758 @default.
• W2128573330 creator A5056093448 @default.
• W2128573330 creator A5057302175 @default.
• W2128573330 creator A5068770175 @default.
• W2128573330 creator A5082204742 @default.
• W2128573330 date "2015-01-28" @default.
• W2128573330 modified "2023-10-13" @default.
• W2128573330 title "Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children" @default.
• W2128573330 cites W1637567005 @default.
• W2128573330 cites W1838568970 @default.
• W2128573330 cites W1968139519 @default.
• W2128573330 cites W1972148175 @default.
• W2128573330 cites W1996418116 @default.
• W2128573330 cites W2032150053 @default.
• W2128573330 cites W2040931088 @default.
• W2128573330 cites W2076340545 @default.
• W2128573330 cites W2076501430 @default.
• W2128573330 cites W2108512502 @default.
• W2128573330 cites W2134129160 @default.
• W2128573330 cites W2136579540 @default.
• W2128573330 cites W2151597897 @default.
• W2128573330 cites W2157656397 @default.
• W2128573330 cites W2161311583 @default.
• W2128573330 doi "https://doi.org/10.1186/s12936-014-0521-2" @default.
• W2128573330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4318246" @default.
• W2128573330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25626448" @default.
• W2128573330 hasPublicationYear "2015" @default.
• W2128573330 type Work @default.
• W2128573330 sameAs 2128573330 @default.
• W2128573330 citedByCount "31" @default.
• W2128573330 countsByYear W21285733302015 @default.
• W2128573330 countsByYear W21285733302016 @default.
• W2128573330 countsByYear W21285733302017 @default.
• W2128573330 countsByYear W21285733302018 @default.
• W2128573330 countsByYear W21285733302019 @default.
• W2128573330 countsByYear W21285733302020 @default.
• W2128573330 countsByYear W21285733302021 @default.
• W2128573330 countsByYear W21285733302022 @default.
• W2128573330 countsByYear W21285733302023 @default.
• W2128573330 crossrefType "journal-article" @default.
• W2128573330 hasAuthorship W2128573330A5002294564 @default.
• W2128573330 hasAuthorship W2128573330A5007865736 @default.
• W2128573330 hasAuthorship W2128573330A5012747021 @default.
• W2128573330 hasAuthorship W2128573330A5013524950 @default.
• W2128573330 hasAuthorship W2128573330A5033765931 @default.
• W2128573330 hasAuthorship W2128573330A5039722694 @default.
• W2128573330 hasAuthorship W2128573330A5043434594 @default.
• W2128573330 hasAuthorship W2128573330A5047557149 @default.
• W2128573330 hasAuthorship W2128573330A5048035758 @default.
• W2128573330 hasAuthorship W2128573330A5056093448 @default.
• W2128573330 hasAuthorship W2128573330A5057302175 @default.
• W2128573330 hasAuthorship W2128573330A5068770175 @default.
• W2128573330 hasAuthorship W2128573330A5082204742 @default.
• W2128573330 hasBestOaLocation W21285733301 @default.
• W2128573330 hasConcept C126322002 @default.
• W2128573330 hasConcept C203014093 @default.
• W2128573330 hasConcept C2776120307 @default.
• W2128573330 hasConcept C2776992834 @default.
• W2128573330 hasConcept C2778048844 @default.
• W2128573330 hasConcept C2778059366 @default.
• W2128573330 hasConcept C2778118209 @default.
• W2128573330 hasConcept C2778371730 @default.
• W2128573330 hasConcept C2778629330 @default.
• W2128573330 hasConcept C2780780316 @default.
• W2128573330 hasConcept C44249647 @default.
• W2128573330 hasConcept C71924100 @default.
• W2128573330 hasConceptScore W2128573330C126322002 @default.
• W2128573330 hasConceptScore W2128573330C203014093 @default.
• W2128573330 hasConceptScore W2128573330C2776120307 @default.
• W2128573330 hasConceptScore W2128573330C2776992834 @default.
• W2128573330 hasConceptScore W2128573330C2778048844 @default.
• W2128573330 hasConceptScore W2128573330C2778059366 @default.
• W2128573330 hasConceptScore W2128573330C2778118209 @default.
• W2128573330 hasConceptScore W2128573330C2778371730 @default.
• W2128573330 hasConceptScore W2128573330C2778629330 @default.
• W2128573330 hasConceptScore W2128573330C2780780316 @default.
• W2128573330 hasConceptScore W2128573330C44249647 @default.
• W2128573330 hasConceptScore W2128573330C71924100 @default.
• W2128573330 hasIssue "1" @default.
• W2128573330 hasLocation W21285733301 @default.
• W2128573330 hasLocation W21285733302 @default.
• W2128573330 hasLocation W21285733303 @default.
• W2128573330 hasLocation W21285733304 @default.
• W2128573330 hasLocation W21285733305 @default.
• W2128573330 hasOpenAccess W2128573330 @default.
• W2128573330 hasPrimaryLocation W21285733301 @default.
• W2128573330 hasRelatedWork W2006887406 @default.
• W2128573330 hasRelatedWork W2108896527 @default.
• W2128573330 hasRelatedWork W2125109931 @default.
• W2128573330 hasRelatedWork W2142960482 @default.

• next